User login
Key clinical point: Patients aged 2 years or older with mild-to-moderate atopic dermatitis (AD) showed a better response to 2% crisaborole ointment than other topical calcineurin inhibitors, such as 1% pimecrolimus and 0.03% tacrolimus.
Major finding: By week 6, the odds of achieving Investigator’s Static Global Assessment score of 0/1 was higher for 2% crisaborole vs. 1% pimecrolimus (odds ratio [OR] 2.03; P < .001) and 0.03% tacrolimus (OR, 1.50; P = .012).
Study details: Findings are from an unanchored matching-adjusted indirect comparison of crisaborole 2% with pimecrolimus 1% and tacrolimus (0.03% and 0.1%) in patients aged 2 years or older who had mild-to-moderate AD using individual patient data from 2 phase 3 randomized controlled trials (RCTs) and comparators used in published RCTs.
Disclosures: This study was funded by Pfizer. The authors declared serving as advisor and speaker and/or receiving consulting fees and funding from several sources. Five employees declared being employees and/or shareholders of Pfizer.
Source: Thom H et al. Dermatol Ther (Heidelb). 2021 (Dec 8). Doi: 10.1007/s13555-021-00646-1.
Key clinical point: Patients aged 2 years or older with mild-to-moderate atopic dermatitis (AD) showed a better response to 2% crisaborole ointment than other topical calcineurin inhibitors, such as 1% pimecrolimus and 0.03% tacrolimus.
Major finding: By week 6, the odds of achieving Investigator’s Static Global Assessment score of 0/1 was higher for 2% crisaborole vs. 1% pimecrolimus (odds ratio [OR] 2.03; P < .001) and 0.03% tacrolimus (OR, 1.50; P = .012).
Study details: Findings are from an unanchored matching-adjusted indirect comparison of crisaborole 2% with pimecrolimus 1% and tacrolimus (0.03% and 0.1%) in patients aged 2 years or older who had mild-to-moderate AD using individual patient data from 2 phase 3 randomized controlled trials (RCTs) and comparators used in published RCTs.
Disclosures: This study was funded by Pfizer. The authors declared serving as advisor and speaker and/or receiving consulting fees and funding from several sources. Five employees declared being employees and/or shareholders of Pfizer.
Source: Thom H et al. Dermatol Ther (Heidelb). 2021 (Dec 8). Doi: 10.1007/s13555-021-00646-1.
Key clinical point: Patients aged 2 years or older with mild-to-moderate atopic dermatitis (AD) showed a better response to 2% crisaborole ointment than other topical calcineurin inhibitors, such as 1% pimecrolimus and 0.03% tacrolimus.
Major finding: By week 6, the odds of achieving Investigator’s Static Global Assessment score of 0/1 was higher for 2% crisaborole vs. 1% pimecrolimus (odds ratio [OR] 2.03; P < .001) and 0.03% tacrolimus (OR, 1.50; P = .012).
Study details: Findings are from an unanchored matching-adjusted indirect comparison of crisaborole 2% with pimecrolimus 1% and tacrolimus (0.03% and 0.1%) in patients aged 2 years or older who had mild-to-moderate AD using individual patient data from 2 phase 3 randomized controlled trials (RCTs) and comparators used in published RCTs.
Disclosures: This study was funded by Pfizer. The authors declared serving as advisor and speaker and/or receiving consulting fees and funding from several sources. Five employees declared being employees and/or shareholders of Pfizer.
Source: Thom H et al. Dermatol Ther (Heidelb). 2021 (Dec 8). Doi: 10.1007/s13555-021-00646-1.